Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.

Shares of GlaxoSmithKline Pharmaceuticals hit the 20 percent upper circuit at ₹2,421.30 per share on the BSE on Monday, February 17, following an impressive financial performance in the quarter ended ...

The company posted a multifold jump per cent in consolidated net profit to Rs 230 crore as compared to Rs 46 crore a year ago ...

The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session.

India's GlaxoSmithKline Pharma reports higher profit on strong demand for respiratory drugs India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

GlaxoSmithKline Pharmaceuticals reported a significant increase in net profit to Rs 229 crore for the third quarter ending December 31, 2024. This growth reflects their commitment to innovative ...

Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents ...

It forecasts that the repurchases - which are due to complete in 18 months - will boost core earnings by 6% to 8% in 2025 ...

Arizona sued drug manufacturer GlaxoSmithKline over what it calls deceptive practices involving the inhaled corticosteroid Flovent that endangered asthma patients. The lawsuit filed Thursday in ...